MDM2 and lymphoma: Consistent with this model, earlier studies conducted in Eμ‐Myc transgenic mice harboring the C305F mutation in MDM2, which disrupts its interaction with RPL11 and the inhibitory effect of the IRBC complex, demonstrated that mutant mice succumb earlier to lymphoma with respect to their WT counterparts (Macias et al, 2010).